---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-26-000033"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2026-06-15T20:06:58+00:00"
generated_at: "2026-06-15T20:16:51.111846+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA accepts Inhibrx BLA for ozekibart in chondrosarcoma; PDUFA date April 14, 2027

## Summary
- FDA accepted BLA for ozekibart (INBRX-109) for unresectable or metastatic conventional chondrosarcoma.
- No filing review issues identified; PDUFA goal date set for April 14, 2027.
- If approved, ozekibart would be first FDA-approved systemic therapy for this indication.
- Pivotal ChonDRAgon trial showed 52% risk reduction in disease progression/death (HR 0.479; p<0.0001).
- Median PFS 5.52 months for ozekibart vs 2.66 months for placebo.

## SEC filing metadata
- accession: 0002007919-26-000033
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2026-06-15T20:06:58+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/0002007919-26-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/inhibrx-20260615.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-26-000033
- JSON: https://secwatch.observer/filing/0002007919-26-000033.json
- Plain text: https://secwatch.observer/filing/0002007919-26-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.